A Study to Determine Whether EGFR Status by FISH Can Predict Results in Non Small Cell Lung Cancer (NSCLC) Patients Treated With Cetuximab, Carboplatin and Paclitaxel

NCT00768131 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Conditions

Lung Neoplasms
Carcinoma, Non-Small-Cell Lung

Interventions

DRUG: Cetuximab
DRUG: Paclitaxel
DRUG: Carboplatin

Sponsor

Eli Lilly and Company